LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Acadia Healthcare to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024 | Last Trade: US$45.06 1.28 2.92

FRANKLIN, Tenn. / Jan 03, 2024 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, at The Westin St. Francis, San Francisco, California. In connection with the conference, there will be a webcast of the Company’s presentation available on the Company’s website starting at 2:15 p.m. Pacific Time/4:15 p.m. Central Time on Tuesday, January 9, 2024.

The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investor Relations” link. A replay of the presentation will also be available on the Company’s website for thirty days.

About Acadia Healthcare

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2023, Acadia operated a network of 253 behavioral healthcare facilities with approximately 11,100 beds in 39 states and Puerto Rico. With approximately 23,000 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page